- Trial phase
- Phase 3
- Time to market
- EU submission completed in Q3 2026; potential EU approval in 2027-2028. US/Japan/China filings delayed pending additional Phase 3 data, launch estimated 2027 or later per Novartis CEO.
- Why 3/10
- No near-term binary catalyst is scheduled. The EU submission was completed in Q3 2026 (a regulatory filing, not a dated decision), and the next hard catalyst would be an EMA decision ~12-18 months out. Pelabresib is a minor pipeline asset for Novartis, a ~$300B+ diversified pharma company with dozens of marketed drugs.
The next catalyst is the EU regulatory decision on pelabresib for myelofibrosis, following the Q3 2026 submission, a typical EMA review takes 12-18 months, so a decision could come in late 2027 or 2028. The ongoing MANIFEST-3 Phase 3 trial (NCT07357727) started May 2026 with 460 patients and completion expected December 2030; interim safety data will be critical to resolving the AML transformation signal. For Novartis, even a positive EU approval would be a modest contributor given the company's diversified portfolio.
Price Chart
Executive Summary
Pelabresib (CPI-0610/DAK539) is an investigational oral BET inhibitor being developed by Novartis (NVS) for myelofibrosis, a rare blood cancer. The Phase 3 MANIFEST-2 trial met its primary endpoint (66% vs 35% spleen volume reduction, p<0.001), but a safety signal, an imbalance in malignant transformations to acute myeloid leukemia, emerged post-acquisition, causing Novartis to delay US regulatory filings by years and take an $800M impairment on its $2.9B MorphoSys buyout. Novartis completed an EU submission in Q3 2026, but US/Japan/China filings await additional Phase 3 data from a new trial (MANIFEST-3) that began enrolling in May 2026. For Novartis, a ~$300B+ diversified pharma giant, pelabresib is a minor pipeline asset with no near-term binary catalyst.
How It Works
Pelabresib is a pill that inhibits BET proteins, which act as 'master switches' that turn on genes involved in inflammation and cancer growth in myelofibrosis. By blocking these proteins, the drug aims to reduce spleen enlargement, improve symptoms, and potentially modify the course of the disease when combined with the standard therapy ruxolitinib (Jakafi).
Trial Status
The pivotal Phase 3 MANIFEST-2 trial (NCT04603495) met its primary endpoint: 66% of patients on pelabresib + ruxolitinib achieved ≥35% spleen volume reduction at week 24 vs 35% on placebo + ruxolitinib (p<0.001). 96-week follow-up data showed durable responses. However, a safety signal involving an imbalance in malignant transformations to acute myeloid leukemia emerged, prompting Novartis to delay US filings. A new Phase 3 trial (MANIFEST-3, NCT07357727) began enrolling 460 patients in May 2026, expected to complete by December 2030. An extension study (NCT06401356) is also recruiting.
The Two-Sided Case
Upcoming Catalysts
- EU regulatory decision on pelabresib for myelofibrosis (submitted Q3 2026; decision expected late 2027-2028)
- MANIFEST-3 Phase 3 trial (NCT07357727) interim data readouts (trial started May 2026, completion Dec 2030)
- Potential US/Japan/China regulatory filings pending additional safety data
Source Filing
The SecBot filing or press-release report that triggered this drug report:
NOVARTIS AG 6-K NVS ·Originating report